Literature DB >> 19004939

Differential sensitivity of "old" versus "new" APOBEC3G to human immunodeficiency virus type 1 vif.

Ritu Goila-Gaur1, Mohammad A Khan, Eri Miyagi, Klaus Strebel.   

Abstract

HIV-1 Vif counteracts the antiviral activity of APOBEC3G by inhibiting its encapsidation into virions. Here, we compared the relative sensitivity to Vif of APOBEC3G in stable HeLa cells containing APOBEC3G (HeLa-A3G cells) versus that of newly synthesized APOBEC3G. We observed that newly synthesized APOBEC3G was more sensitive to degradation than preexisting APOBEC3G. Nevertheless, preexisting and transiently expressed APOBEC3G were packaged with similar efficiencies into vif-deficient human immunodeficiency virus type 1 (HIV-1) virions, and Vif inhibited the encapsidation of both forms of APOBEC3G into HIV particles equally well. Our results suggest that HIV-1 Vif preferentially induces degradation of newly synthesized APOBEC3G but indiscriminately inhibits encapsidation of "old" and "new" APOBEC3G.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19004939      PMCID: PMC2612393          DOI: 10.1128/JVI.01734-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

2.  Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.

Authors:  Andrew Mehle; Bettina Strack; Petronela Ancuta; Chengsheng Zhang; Mark McPike; Dana Gabuzda
Journal:  J Biol Chem       Date:  2003-12-13       Impact factor: 5.157

3.  The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.

Authors:  Silvestro G Conticello; Reuben S Harris; Michael S Neuberger
Journal:  Curr Biol       Date:  2003-11-11       Impact factor: 10.834

4.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.

Authors:  Bindong Liu; Xianghui Yu; Kun Luo; Yunkai Yu; Xiao-Fang Yu
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

6.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.

Authors:  Hui Zhang; Bin Yang; Roger J Pomerantz; Chune Zhang; Shyamala C Arunachalam; Ling Gao
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

7.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Authors:  Bastien Mangeat; Priscilla Turelli; Gersende Caron; Marc Friedli; Luc Perrin; Didier Trono
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

8.  HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.

Authors:  Mariana Marin; Kristine M Rose; Susan L Kozak; David Kabat
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

9.  HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.

Authors:  Kim Stopak; Carlos de Noronha; Wes Yonemoto; Warner C Greene
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

10.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.

Authors:  Ann M Sheehy; Nathan C Gaddis; Michael H Malim
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

View more
  13 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  APOBEC3G: a double agent in defense.

Authors:  Harold C Smith
Journal:  Trends Biochem Sci       Date:  2011-01-14       Impact factor: 13.807

3.  RNA binding to APOBEC3G induces the disassembly of functional deaminase complexes by displacing single-stranded DNA substrates.

Authors:  Bogdan Polevoda; William M McDougall; Bradley N Tun; Michael Cheung; Jason D Salter; Alan E Friedman; Harold C Smith
Journal:  Nucleic Acids Res       Date:  2015-09-30       Impact factor: 16.971

4.  Direct evidence that RNA inhibits APOBEC3G ssDNA cytidine deaminase activity.

Authors:  William M McDougall; Harold C Smith
Journal:  Biochem Biophys Res Commun       Date:  2011-08-11       Impact factor: 3.575

5.  Interaction between Nef and INI1/SMARCB1 augments replicability of HIV-1 in resting human peripheral blood mononuclear cells.

Authors:  Dohun Pyeon; In-Woo Park
Journal:  Arch Virol       Date:  2015-01-07       Impact factor: 2.574

Review 6.  Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.

Authors:  Laurence Colin; Carine Van Lint
Journal:  Retrovirology       Date:  2009-12-04       Impact factor: 4.602

Review 7.  Human cellular restriction factors that target HIV-1 replication.

Authors:  Klaus Strebel; Jeremy Luban; Kuan-Teh Jeang
Journal:  BMC Med       Date:  2009-09-16       Impact factor: 8.775

Review 8.  HIV accessory proteins versus host restriction factors.

Authors:  Klaus Strebel
Journal:  Curr Opin Virol       Date:  2013-11-15       Impact factor: 7.090

9.  Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion.

Authors:  Eri Miyagi; Amy J Andrew; Sandra Kao; Klaus Strebel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

Review 10.  Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment.

Authors:  Mahdis Monajemi; Claire F Woodworth; Jessica Benkaroun; Michael Grant; Mani Larijani
Journal:  Retrovirology       Date:  2012-04-30       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.